Race Oncology is pleased to announce that it has appointed the clinical and regulatory strategy advisor, CCS Associates (CCSA, California, USA) to advise on development options for Bisantrene as an…

Our executive leaders discuss the benefits of a shared leadership model and the experience they each bring to Race Oncology. https://youtu.be/ebXA6rD5pRs

1 September 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that it has expanded its executive team with the appointment of Mr Phil Lynch as Chief Executive…

Dear Shareholders It is my pleasure to formally open the annual report to Race Oncology Shareholders for the period ended 30 June 2020. It’s been a highly successful year as…

Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology's CSO Dr Daniel Tillett at the IRD Invest virtual conference…